HLX-25

N/A

Report date: 2024/12/13 16:57:23

Base Information

Drug NameHLX-25
Drug Alias NameHLX-25
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 inhibitors
TargetsTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A